Search
Get in touch!
Linkedin X-twitter Envelope

Christopher Davis: Letter to Shareholders Fall 2024

In his recent letter to shareholders, Christopher Davis highlights that the era of near-zero interest rates, which began after the 2008 financial crisis, ended in March 2022 when the Federal Reserve started raising rates. This shift marks a return to a more normal economic environment, though it may bring volatility and disruptions.

Christopher expresses optimism about long-term progress and innovation, despite current challenges and pessimism and has positioned the portfolio around four main themes:

  • Financials: Focusing on banks with misunderstood durability and strength.
  • Technology: Investing in resilient growth at reasonable prices, avoiding overvalued market darlings.
  • Healthcare: Targeting companies that create value by moderating healthcare costs.
  • Industrials: Seeking businesses with resilient, non-linear growth and inflation protection.

Here are the key takeaways:

  • The end of the “free-money era” is leading to market normalization, which may benefit value-oriented investors.
  • The fund’s strategy focuses on companies with cash generation, conservative capital structures, durable business models, low valuations, and proven management.
  • While acknowledging current challenges, Christopher maintains a long-term optimistic outlook on human progress and innovation. He sees the advent of generative AI is seen as transformational, but approaches it cautiously, avoiding hype and focusing on companies that can effectively use the technology to build value.

From 2008-2022, artificially suppressed interest rates created a period of unprecedented economic and market distortion. Throughout that period, fundamental investment analysis—which rests on discounted present value, cost of capital and risk management—became largely irrelevant. Valuation discipline fell out of favor and the market increasingly rewarded momentum and speculation.

Click here to go to the external source.

Share the news

Disclaimer of liability

The above has been prepared by Børsgade ApS for information purposes and cannot be regarded as a solicitation or recommendation to buy or sell any security. Nor can the information etc. be regarded as recommendations or advice of a legal, accounting or tax nature. Børsgade cannot be held liable for losses caused by customers’/users’ actions – or lack thereof – based on the information in the above. We have made every effort to ensure that the information in the above is complete and accurate, but cannot guarantee this and accept no liability for errors or omissions.

Readers are advised that investing may involve a risk of loss that cannot be determined in advance, and that past performance and price development cannot be used as a reliable indicator of future performance and price development. For further information please contact info@borsgade.dk

You might also find this interesting:

Michael Mauboussin: Drawdowns Are The Unavoidable Cost of Long-Term Investing

June 6, 2025

Michael Mauboussin from Morgan Stanley Investment Management have published a comprehensive analysis examining stock market drawdowns and recovery patterns from 1985 to 2024. The research reveals that even the most successful investments experience severe price declines, with the median stock suffering an 85% drawdown that takes 2.5 years from peak to trough.

The study analyzed over 6,500 companies and found that more than half never recover to their previous highs. Michael’s work demonstrates that large drawdowns are an inevitable feature of equity investing, affecting individual stocks, mutual funds, and even portfolios with perfect foresight.

Thomas Gayner: My Current Take on Novo Nordisk

June 6, 2025

In his interview, Tom Gayner, CEO of Markel Group, reflects on investment principles shaped by Warren Buffett and Charlie Munger, and offers a detailed assessment of Novo Nordisk. Gayner praises Novo Nordisk for its business quality, global leadership in diabetes treatment, and strong growth trajectory. He credits the company’s disciplined management and innovation in pharmaceuticals as exemplary, aligning with his own standards of long-term value creation.

Michael Mauboussin: Put Expected Value In Your Valuation Toolkit

May 21, 2025

In this article, Michael Mauboussin explores how investors can generate excess returns by focusing on the gap between price and value, emphasizing the practicalities and psychology of expected value in investment decisions. He explains that while price is observable, value is inherently probabilistic, requiring careful estimation of possible payoffs and their probabilities.

The paper covers the challenges of modeling uncertainty, the importance of considering both probabilities and payoffs, the psychological hurdles investors face (like loss aversion), and best practices for applying these concepts across asset classes.

Bill Ackman: Success is Not A Straight Line Up

May 21, 2025

In the 2025 UBS Berkshire Hathaway Fireside Chat, Bill Ackman and Ryan Israel from Pershing Square Capital discuss investment philosophy, market volatility, the impact of tariffs and geopolitics, and lessons from Warren Buffett.

The conversation covers how to identify durable, high-quality businesses, the importance of long-term thinking, and the evolving landscape for activist investing. Ackman shares personal reflections on resilience, mentorship, and the role of free speech, while both speakers provide practical advice for young investors and fund managers.